Target intelligence / Profile preview

Chondroitin 6-sulfate (C6S)

Target
C6S
Molecular classification
Glycosaminoglycan, Polysaccharide, Other
01

Overview

Chondroitin 6-sulfate (C6S), also known as chondroitin sulfate C, is a sulfated glycosaminoglycan (GAG) composed of alternating glucuronic acid and N-acetylgalactosamine residues sulfated at the C6 position. It is a major component of the extracellular matrix (ECM) in cartilage, blood vessels, and the central nervous system, where it plays critical roles in maintaining structural integrity, regulating cell signaling, and modulating cell adhesion and migration. In pathological states, such as Mucopolysaccharidosis IVA (Morquio A syndrome), a deficiency in the lysosomal enzyme N-acetylgalactosamine-6-sulfatase (GALNS) leads to the toxic accumulation of C6S and keratan sulfate, which is treated with the enzyme replacement therapy elosulfase alfa. Additionally, altered sulfation patterns of chondroitin sulfate, including oncofetal chondroitin sulfate (ofCS) which is highly enriched in C6S motifs, are aberrantly expressed in solid tumors and the tumor microenvironment, making them attractive targets for novel cancer therapies like Vartumab. In central nervous system injuries, C6S is upregulated in the glial scar and acts as a barrier to axonal regeneration, which researchers are targeting using C6S-binding peptides and chondroitinase enzymes to promote functional recovery.

Other names
Chondroitin sulfate CChondroitin sulfate type CCS-C6-O-sulfated chondroitin sulfate
02

Mechanism of action

Enzymatic degradation of accumulated glycosaminoglycans to restore tissue homeostasis; competitive binding to block inhibitory or pro-tumorigenic interactions; targeting of oncofetal chondroitin sulfate to deliver cytotoxic payloads (ADCs) or recruit T-cells.

03

Biological functions

Extracellular matrix assemblyCell signalingCell adhesionAxonal growth regulationOther
04

Disease associations

Mucopolysaccharidosis IVACancerSpinal cord injuryAtherosclerosisOsteoarthritisOther
05

Safety considerations

Hypersensitivity reactions and anaphylaxis associated with enzyme replacement therapiesRisk of spinal or cervical compression in MPS IVA patientsPotential off-target degradation of healthy extracellular matrixImmunogenicity of bacterial-derived enzymes such as chondroitinase ABC
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

Chondroitin 6-sulfate levelsKeratan sulfate levelsOncofetal chondroitin sulfate (ofCS) expression

Beyond the preview

Go deeper on Chondroitin 6-sulfate (C6S).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chondroitin 6-sulfate (C6S).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call